0QB4 Stock Overview
Medios AG, together with its subsidiaries, supplies specialty pharmaceutical drugs primarily in Germany.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Medios AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €14.36 |
| 52 Week High | €18.55 |
| 52 Week Low | €13.30 |
| Beta | 1.07 |
| 1 Month Change | -12.26% |
| 3 Month Change | -2.73% |
| 1 Year Change | -19.52% |
| 3 Year Change | -59.67% |
| 5 Year Change | -15.54% |
| Change since IPO | -4.10% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0QB4 | GB Healthcare | GB Market | |
|---|---|---|---|
| 7D | -0.4% | 1.4% | 2.7% |
| 1Y | -19.5% | -29.1% | 0.3% |
Return vs Industry: 0QB4 exceeded the UK Healthcare industry which returned -29.1% over the past year.
Return vs Market: 0QB4 underperformed the UK Market which returned 0.3% over the past year.
Price Volatility
| 0QB4 volatility | |
|---|---|
| 0QB4 Average Weekly Movement | 8.9% |
| Healthcare Industry Average Movement | 7.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0QB4 has not had significant price volatility in the past 3 months.
Volatility Over Time: 0QB4's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 424 | Matthias Gaertner | www.medios.ag |
Medios AG, together with its subsidiaries, supplies specialty pharmaceutical drugs primarily in Germany. It operates through Pharmaceutical Supply and Patient-Specific Therapies segments. The Pharmaceutical Supply segment offers products on oncology, neurology, autoimmunology, ophthalmology, infectiology, and hemophilia diseases.
Medios AG Fundamentals Summary
| 0QB4 fundamental statistics | |
|---|---|
| Market cap | €342.80m |
| Earnings (TTM) | €18.81m |
| Revenue (TTM) | €1.78b |
18.2x
P/E Ratio0.2x
P/S RatioIs 0QB4 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0QB4 income statement (TTM) | |
|---|---|
| Revenue | €1.78b |
| Cost of Revenue | €1.68b |
| Gross Profit | €108.63m |
| Other Expenses | €89.82m |
| Earnings | €18.81m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 07, 2024
| Earnings per share (EPS) | 0.79 |
| Gross Margin | 6.09% |
| Net Profit Margin | 1.05% |
| Debt/Equity Ratio | 0% |
How did 0QB4 perform over the long term?
See historical performance and comparison